Biotech entity
Of the tracked stories, 5 of 5 also mention Novo Nordisk, the most common co-covered peer. Across a 218-day span, the pace is roughly 0.2 stories per week. The busiest single day carried 2. Coverage clusters in pharma, which accounts for 3 of those 5, with the remainder spread across 1 other category.
Last mentioned: Sep 24, 2026
Entity pulse
Coverage balance Negative coverage leads. Negative coverage exceeds positive coverage by 20 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Of the tracked stories, 5 of 5 also mention Novo Nordisk, the most common co-covered peer. Across a 218-day span, the pace is roughly 0.2 stories per week. The busiest single day carried 2. Coverage clusters in pharma, which accounts for 3 of those 5, with the remainder spread across 1 other category. Negative sentiment reaches 40% here, compared with 16% across the 809-story beat baseline for the same window. At 6.6, the average consequence score sits above the same-window beat average of 6.1. Source depth averages 3.2 original sources per story, versus 3.4 across the same-window beat baseline. We currently track 5 Biotech stories that mention GLP-1 Receptor Agonists, published between February 19, 2026 and September 24, 2026.
Computed from the 5 stories linked to this entity, with beat comparisons drawn from all 809 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering GLP-1 Receptor Agonists. Shared-story counts are live from our verified record — not editorial picks.
European Respiratory Society presentation
Professor Chloe Bloom presents a real-world UK electronic medical record analysis linking GLP-1 receptor agonists, particularly semaglutide, to fewer asthma attacks and COPD flare-ups.
Lawsuit Filed
Novo Nordisk sues Eli Lilly in the U.S. District Court for the District of New Jersey, alleging false advertising and unfair competition under the Lanham Act.
FDA Approves Wegovy 7.2 mg
Novo Nordisk receives U.S. approval for a higher-dose semaglutide injection for obesity, backed by the STEP UP trial showing 19% average weight loss.
Novo Nordisk and Eli Lilly face a growing NAION safety-signal dispute as nearly 100 lawsuits mount. Mixed epidemiological data puts GLP-1 class safety and potential label implications under scrutiny.
Observational data link semaglutide and tirzepatide to a modest increase in NAION and other optic nerve disorders, raising questions for GLP-1 developers about class-effect risk and label differentiation.
Source: whio.com · fox26houston.com
Biopharma teams now have a strong observational signal that semaglutide could address asthma and COPD exacerbations, but a new indication will require prospective randomized trials. The findings may shape GLP-1 lifecycle strategies and respiratory pipeline investment.
Source: turnto23.com · abc15.com
The litigation underscores the GLP-1 dosing race: Wegovy 7.2 mg’s clinical superiority reshapes head-to-head comparisons, forcing Lilly to legally defend its ad strategy amid rapid innovation.
As GLP-1 receptor agonists like semaglutide and tirzepatide dominate the obesity market, the focus is shifting toward integrated nutritional strategies to mitigate muscle loss and gastrointestinal side effects. This evolution marks a transition from simple weight reduction to comprehensive body composition management.
GLP-1 Receptor Agonists is linked from 5 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
